Conceptos actuates en el diagnóstico y tratamiento de la acromegalia

Revista Clinica Espanola

Volumn 196, Issue 9, 1996, Pages 622-635

  Diez J J ^a,b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; METABOLISM;

ACROMEGALY; HUMANS;

EID: 0029796931     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (279)

1. Barkan AL, Shenker Y, Grekin RJ, et al. Acromegaly due to ectopic growth hormone (GH)-releasing hormone (GHRH) production, dynamic studies of GH and ectopic GHRH secretion J Clin Endocrinol Metab 1986; 63.1.057-1 064
2. Melmed S, Rushakoff RJ. Ectopic pituitary and hypothalamic hormone syndromes. Endocrinol Metab Clin North Am 1987. 16:805-821.
3. Faglia G, Arosio M, Bazzoni N. Ectopic acromegaly Endocrinol Metab Clin North Am 1992, 21.575-595.
4. Losa M, Schopohl J, Von Werder K Ectopic secretion of growth hormone-releasing hormone in man. J Endocrinol Invest 1993, 16:69-81.
5. Ezzat S, Asa SL, Stefaneau L, et al. Somatotroph hyperplasia without pituitary adenoma associated with a long standing growth hormone-relasing hormone-producing bronchial carcinoid. J Clin Endocrinol Metab 1994; 78:555-560.
6. Alexander L, Appleton D, Hall R, et al. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxford) 1980; 12:71-79.
7. Bengtsson BA, Edén S, Ernest I, et al Epidemiology and long term survival in acromegaly A study of 166 cases diagnosed between 1955 and 1984 Acta Med Scand 1988; 223.327-335.
8. Etxabe J, Gaztambide S, Latorre P, Vázquez JA. Acromegaly. an epidemiological study J Endocrinol Invest 1993, 16.181-187.
9. Nabarro JDN Acromegaly. Clin Endocrinol (Oxford) 1987; 26 481-512.
10. Melmed S. Acromegaly. N Engl J Med 1990; 322:966-977.
11. Ezzat S, Forster MJ, Berchtold P, et al. Acromegaly. Clinical and biochemical features in 500 patients. Medicine (Baltimore) 1994; 73:233-240.
12. Benlian P, Giraud S, Lahlou N, et al. Familiar acromegaly: a specific clinical entity-further evidence from the genetic study of a three-generation family. Eur J Endocrinol 1995; 133:451-456
13. Wright AD, Hill DM, Lowy C, Fraser TR. Mortality in acromegaly. Q J Med 1970; 39:1-16.
14. Bates AS. Van't Hoff W, Jones JM, Clayton RN An audit of outcome of treatment in acromegaly. Q J Med 1993, 86:293-299.
15. Bates AS, Van't Hoff W, Jones JM, Clayton RN. Does treatment of acromegaly affect life expectancy? Metabolism 1995, 44 (suppl 1):1-5.
16. Ron E, Gridley G, Hrubec Z, et al. Acromegaly and gastrointestinal cancer. Cancer 1991; 68:1.673-1.677.
17. Baumann G. Acromegaly Endocrinol Metab Clin North Am 1987; 16:685-703.
18. a ed). Philadelphia: WB Saunders, 1992; 221-310.
19. Molitch ME. Clinical manifestations of acromegaly. Endocrinol Metab Clin North Am 1992; 21:597-614
20. Gómez-Pan A, Díez JJ. Acromegalia. Medicine 1993; 6: 1.285-1.293.
21. Rajasoorya C, Holdaway IM, Wrightson P, et al. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxford) 1994; 41:95-102
22. Melmed S. Acromegaly. En: Melmed S, ed The pituitary. Cambridge (MA): Blackwell Science. 1995; 413-442.
23. a ed). Nueva York. McGraw-Hill, 1995; 289-383.
24. Lamberts SWJ, Van der Lely AJ, De Herder WW. Clinical and medical diagnosis of acromegaly. Metabolism 1995, 44 (suppl 1):15-17.
25. Melmed S, Fagin J. Acromegaly update. West J Med 1985, 146: 328-336.
26. Thorner MO, Hartman ML, Vance ML. Clinical aspects of growth hormone hypersecretion. En: Lamberts SWJ, ed. Sandostatin in the treatment of acromegaly Berlin: Springer-Verlag, 1988; 1-7.
27. Hennessey JV, Jackson IMD Clinical features and differential diagnosis of pituitary tumours with enphasis on acromegaly Baillière's Clin Endocrinol Metab 1995; 9.271-314.
28. Wass JAH. Acromegaly: treatment after 100 years Br Med J 1993; 307.1.505-1 506
29. Klein I, Parveen G, Gavaler JS, Van Thiel DH. Colonic polyps in patients with acromegaly. Ann Intern Med 1982, 97.27-30
30. Ituarte EM, Petrini J, Hershman JM. Acromegaly and colon cancer. Ann Intern Med 1984; 101:627-628.
31. Pines A, Rozen P, Ron E, Gilat T. Gastrointestinal tumors in acromegalic patients. Am J Gastroenterol 1985; 80-266-269.
32. Ezzat S, Melmed S. Are patients with acromegaly at increased risk for neoplasia? J Clin Endocrinol Metab 1991, 72:245-249
33. Ezzat S, Strom C, Melmed S. Colon polyps in acromegaly. Ann Intern Med 1991; 114:754-755.
34. Ladas SE, Thalassinos NC, Ioannides G, Raptis SA. Does acromegaly really predispose to an increased prevalence of gastrointestinal tumours? Clin Endocrinol (Oxford) 1994; 41-597-601.
35. Ortego J, Vega B, Sampedro J, et al. Neoplastic colonic polyps in acromegaly Horm Metab Res 1994; 26-609-610
36. Leavitt J, Klein I, Kendricks F, et al Skin tags: a cutaneous marker for colonic polyps. Ann Intern Med 1983, 98.928-930.
37. McGuffin WL, Sherman BM, Roth J, et al. Acromegaly and cardiovascular disorders A prospective study. Ann Intern Med 1974; 81: 11-18.
38. Smallridge RC. Rajfer S, Davia J, Shaff M. Acromegaly and the heart. An echocardiographic study. Am J Med 1979; 66.22-27.
39. Rodrigues EA, Caruana MP, Lahin A, et al. Subclinical cardiac dysfunction in acromegaly evidence for a specific disease of heart muscle. Br Heart J 1989; 62:185-194
40. Grunstein RR, Ho KY, Sullivan CE. Sleep apnea in acromegaly. Ann Intern Med 1991; 115.527-532
41. Rosenow F, Reuter S, Szelies B, et al. Sleep apnoea in acromegaly-prevalence, pathogenesis and therapy. Report on two cases. Press Med 1994, 23.1.203-1.208
42. Mickelson SA, Rosenthal LD, Rock JP, et al Obstructive sleep apnea syndrome and acromegaly. Otolaryngol Head Neck Surg 1994; 111:25-30.
43. Leibowitz G, Shapiro MS, Salameh M, Glaser B. Improvement of sleep apnoea due to acromegaly during short-term treatment with octreotide. J Intern Med 1994; 236-231-235.
44. Grunstein RR, Ho KK, Sullivan CE Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly. Ann Intern Med 1994; 121:478-483.
45. Ho KY, Jenkins AB, Furier SM, et al Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly Clin Endocrinol (Oxford) 1992; 36:271-279
46. Hansen I, Tsalikian E, Beaufrere B, et al. Insulin resistance in acromegaly. defects in both hepatic and extrahepatic insulin action. Am J Phisiol 1986, 250:E269-273.
47. Sonksen PH, Greenwood FC, Ellis JP, et al Changes of carbohydrate tolerance in acromegaly with progress of the disease and in response to treatment J Clin Endocrinol 1967; 27:1.418-1 430
48. Dons RF, Rosselet P, Pastakia B, et al. Arthropathy in acromegalic patients before and after treatment a long-term follow-up study. Clin Endocrinol (Oxford) 1988; 28:515-524.
49. Lieberman SA, Björkengren AG, Hoffman AR. Rheumatologic and skeletal changes in acromegaly. Endocrinol Metab Clin North Am 1992; 21:615-631
50. Klijn JGM, Lamberts SWJ, de Jong FH, et al. Interrelationships between tumor size, age, plasma growth hormone and incidence of extrasellar extension in acromegalic patients. Acta Endocrinol (Copenh) 1980; 95.289-297.
51. Maugans TA, Coates ML. Diagnosis and treatment of acromegaly. Am Fam Physician 1995; 52:207-213.
52. King WA. Management of growth hormone-secreting pituitary adenomas-early diagnosis leads to successful treatment. West J Med 1993; 158:68.
53. Chang-DeMoranville BM, Jackson IMD. Diagnosis and endocrine testing in acromegaly. Endocrinol Metab Clin North Am 1992; 21:649-668.
54. Daughaday WH. New criteria for evaluation of acromegaly. N Engl J Med 1979; 301:1.175-1 176.
55. Lamberton RP, Jackson IMD. Investigation of hypothalamic-pituitary disease. Endocrinol Metab Clin North Am 1983; 12:509-533
56. Hatton N, Shimatsu A, Kato Y, et al. Growth hormone responses to oral glucose loading measured by highly sensitive enzyme immunoassay in normal subjects and patients with glucose intolerance and acromegaly, J Clin Endocrinol Metab 1990; 70:771-776.
57. Barkan AL. Acromegaly. Diagnosis and therapy. Endocrinol Metab Clin North Am 1989; 18:277-310.
58. Clemmons DR, Van Wyk JJ, Ridgway EC, et al. Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med 1979; 301:1 138-1.142.
59. Imura H, Kato Y, Hatton N. Acromegaly, En. Bercu B, ed. Basic and clinical aspects of growth hormone. New York: Plenum Press, 1988; 95-103.
60. Daughaday WH, Starkey RH, Saltman S, et al. Characterization of serum growth hormone (GH) and insulin-like growth factor I in active acromegaly with minimal elevation of serum GH. J Clin Endocrinol Metab 1987; 65:617-623.
61. Rieu M, Girard F, Bricaire H, Binoux M. The importance of insulinlike growth factor (somatomedin) measurements in the diagnosis and surveillance of acromegaly. J Clin Endocrinol Metab 1982; 55:147-153.
62. Ho KY, Weissberger AJ. Characterization of 24-hour growth hormone secretion in acromegaly, implications for diagnosis and therapy. Clin Endocrinol (Oxford) 1994; 41:75-83.
63. Copeland KC, Underwood LE, Van Wyk JJ. Induction of immunoreactive somatomedin-C in human serum by growth hormone: dose-response relationships and effect on chromatographic profiles. J Clin Endocrinol Metab 1980; 50:690-697
64. Barreca A, Ciccarelli E, Minuto F, et al. Insulin-like growth factor I and daily growth hormone profile in the assessment of active acromegaly. Acta Endocrinol (Copenh) 1989; 120:629-635.
65. Hartman ML, Veldhuis JD, Vance ML, et al Somatotropin pulse frequency and basal concentrations are increased in acromegaly and are reduced by succesful therapy. J Clin Endocrinol Metab 1990; 70:1.375-1 384.
66. Losa M, Oeckler R, Schopohl J, et al. Evaluation of selective transsphenoidal adenectomy by endocrinological testing and somatomedin-C measurement in acromegaly. J Neurosurg 1989; 70:561-567.
67. Roelfsema F, Fröhch M, Van Dulken H Somatomedin-C levels in treated and untreated patients with acromegaly. Clin Endocrinol (Oxford) 1987, 26.137-144.
68. Winer L, Shaw MA, Bauman C. Basal plasma growth hormone levels in man: new evidence for rhythmicity of growth hormone secretion J Clin Endocrinol Metab 1990, 70:1 687-1.696.
69. Jaffe LS, Rosen HN Normal insulin-like growth factor-I in an elderly woman with acromegaly and medical illness. Arch Intern Med 1994; 154:1.533-1.535.
70. Lamberts SW, De Herder WW, Kwekkeboom DJ, et al. Current tools in the diagnosis of pituitary tumours Acta Endocrinol (Copenh) 1993; 129 (suppl 1):6-12.
71. Jaffe CA, Barkan AL. Acromegaly. Recognition and treatment Drugs 1994; 47:425-445.
72. Jasper H, Chervin A, Vitale M, et al. Biochemical markers of acromegalic activity Medicina B Aires 1994; 54.25-30
73. Hizuka N, Takano K, Tanaka I, et al. Demonstration of insulin-like growth factor in the urine. J Clin Endocrinol Metab 1987; 64:1 309-1.312
74. Hizuka N, Takano K, Asakawa K, et al. Urinary IGF-I measurement and its clinical application Acta Paediatr Scand (suppl) 1988; 347:127-133.
75. Halimi S, Tepavcevic D, Suchanek D, et al. Eur J Clin Chem Clin Biochem 1994; 32-705-707
76. Casanueva FF Physiology of growth hormone secretion and action. Endocrinol Metab Clin North Am 1992; 21 483-517
77. Barkan AL Stred SE, Reno K, et al. Increased growth hormone pulse frequency in acromegaly J Clin Endocrinol Metab 1989; 69:1.225-1.233.
78. Lunt H, Tucker A, Bullen H, et al. Overnight urinary growth hormone measurement in the diagnosis of acromegaly Clin Endocrinol (Oxford) 1990; 33:205-212.
79. Winer L, Shaw MA, Bauman C, Urinary growth hormone excretion rates in normal and acromegalic man, a clinical appraisal of its potential clinical utility. J Endocrinol Invest 1989; 12:461-467.
80. Main KM, Lindholm J, Vanderweghe M, Skakkebaek NE. Urinary growth hormone excretion in acromegaly: diagnostic value in mild disease activity. Acta Endocrinol (Copenh) 1993; 129.409-413.
81. Pholséna M, Le Boue Y, Rousseau E, et al. Evaluation of acromegaly by measurement of 24-hourly urinary growth hormone excretion. Acta Endocrinol (Copenh) 1993; 128:9-14.
82. Bates AS, Evans AJ, Jones P, Clayton RN Assessment ot GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion. Clin Endocrinol (Oxford) 1995; 42.417-423.
83. Fredstorp L, Werner S, Growth hormone and insulin-like growth factor-1 in blood and urine as response markers during treatment of acromegaly with octreotide: a double-blind placebo-controlled study. J Endocrinol Invest 1993, 16:253-258.
84. Irie M, Tsushima T. Increase of serum growth hormone concentration following thyrotropin-releasing hormone injection in patients with acromegaly or gigantism J Clin Endocrinol Metab 1972; 35:97-100.
85. Faglia G, Beck-Peccoz P, Ferrari G, et al. Plasma growth hormone release to thyrotropin releasing hormone in patients with active acromegaly J Clin Endocrinol Metab 1973; 36 1 259-1 262
86. Maeda K, Kato Y, Yamaguchi N, et al. Growth hormone release following thyrotropin releasing hormone injection into patients with anorexia nervosa. Acta Endocrinol (Copenh) 1976; 81:1-8.
87. Collu R, LeBoeuf G, Letarte J, Ducharme JR. Increase in plasma growth hormone levels following thyrotropin-releasing hormone injection in children with primary hypothyroidism. J Clin Endocrinol Metab 1977; 44:743-747.
88. Díez JJ, Iglesias PL, Sastre J, et al. Influence of erythropoietin on paradoxical responses of growth hormone to thyrotropin-releasing hormone in uremic patients. Kidney Int 1994, 46.1 387-1.391.
89. Dasmahapatra A, Urdanavia E, Cohen MP. Growth hormone response to thyrotropin-releasing hormone in diabetes. J Clin Endocrinol Metab 1981; 52:859-862
90. Zanoboni A, Zanoboni-Muciacca W. Elevated basal growth hormone levels and growth hormone responses to TRH in alcoholic patients with cirrhosis. J Clin Endocrinol 1977; 45:576-578.
91. De Marinis L, Mancini A, Zuppi P. et al. Paradoxical growth hormone response to thyrotropin releasing hormone in active acromegaly. Clinical correlations and prognostic value. Acta Endocrinol (Copenh) 1990; 122:433-449.
92. Samaan N, Leavens M, Jesse R. Serum growth hormone and prolactin response to thyrotropin-releasing hormone in patients with acromegaly before and after surgery. J Clin Endocrinol Metab 1974; 38:957-963.
93. Liuzzi A, Chiodini PG, Botalla L, et al. Growth hormone (GH)-releasing activity of TRH and GH-lowering effect of dopaminergic drugs in acromegaly: homogeneity in the two responses J Clin Endocrinol Metab 1974; 39 871-876.
94. Brockmeier SJ, Buchfelder M, Fahlbusch R. TRH/GnRH test in acromegaly. Long-term follow-up experience with successfully treated patients. Horm Metab Res 1993; 25:275-277.
95. Díez JJ, Gómez-Pan A, Iglesias P Hacia un concepto del síndrome de deficiencia de hormona del crecimiento en adultos. Med Clin (Barc) 1996 (en prensa)
96. Martin JL, Baxter RC Insulin-like growth factor binding protein from human plasma. Purification and characterization. J Biol Chem 1986, 261 8.754-8.760
97. Furlanetto RW. The somatomedin binding protein: evidence for heterologous subunit structure J Clin Endocrinol Metab 1980; 51:12-19.
98. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocrine Rev 1995; 16:3-34.
99. Counts D, Gwirtsman H, Carlsson M, et al The effec of anorexia nervosa and refeeding on growth hormone-binding protein, the insulin-like growth factors (IGFs) and the IGF-binding proteins. J Clin Endocrinol Metab 1992, 75:762-767.
100. Grinspoon S, Clemmons D, Swearingen B, Klibanski A. Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly. J Clin Endocrinol Metab 1995; 80:927-932.
101. Suikkan A, Koivisto VA, Rutanen E. Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein J Clin Endocrinol Metab 1988, 66:266-272.
102. Suikkari A, Koivisto VA, Koistinen R, et al. Dose response characteristics for suppression of low molecular weight plasma insulin-like growth factor-binding protein by insulin. J Clin Endocrinol Metab 1989, 68:135-140.
103. Cohen P, Fielder PJ, Hasegawa Y, et al Clinical aspects of insulin-like growth factor binding proteins Acta Endocrinol (Copenh) 1991; 124 (suppl 2).74-85.
104. Ezzat S, Ren S, Braunstein GD, Melmed S. Octreotide stimulates insulin-like growth factor binding protein-1 (IGFBP-1) levels in acromegaly. J Clin Endocrinol Metab 1991; 73:441-443.
105. Schulte HM, Benker G, Windeck R, et al. Failure to respond to growth-hormone releasing hormone (GHRH) in acromegaly due to a GHRH secreting pancreatic tumor dynamics of multiple endocrine testing. J Clin Endocrinol Metab 1985; 61-585-587.
106. Rappaport R Contribution of magnetic resonance imaging to the diagnosis of pituitary diseases. En: Prader A, Rappaport R, eds. Serono Colloquia Europe Series, vol 1 Clinical Issues in Growth Disorders: Evaluation, diagnosis and therapy London: Freund Publishing House, 1994: 153-162.
107. Pressman BD Pituitary imaging. En: Melmed S. ed. The pituitary. Cambridge (MA): Blackwell Science, 1995: 663-686.
108. De Herder WW, Lamberts SWJ. Imaging of pituitary tumours Baillière's Clin Endocrinol Metab 1995; 9.367-389.
109. Haughton VM, Rimm AA, Czervionke LF, et al. Sensitivity of Gd-DTPA-enhanced MR imaging of benign extraaxial tumors. Radiology 1988; 166:829-833
110. Wolpert SM. The radiology of pituitary adenomas. Endocrinol Metab Clin North Am 1987, 16 553-584
111. Hardy JJ. Transsphenoidal surgery of hypersecreting pituitary tumors En: Kohler PO, Ross GT, eds Diagnosis and treatment of pituitary Tumors. New York: Elsevier Publishing Co. Inc., 1973; 179-194.
112. Reubi JC, Landolt AM. High density of somatostatin receptors in pituitary tumors from acromegalic patients. J Clin Endocrinol Metab 1984; 59:1.1 48-1.152.
113. Krenning EP, Bakker WH, Breeman WAP, et al. Localization of endocrine related tumours with radioiodinated analogue of somatostatin. Lancet 1989; 1:242-244
114. Lamberts SWJ, Bakker WH, Reubi JC. Krenning EP Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med 1900; 323 1 246-1.249
115. Westline JE, Tiensuu Janson E, Ahlström H. et al. Scintigraphy using a 111-indium-labeled somatostatin analogue for localization of neuroendocrine tumors. Antibody Immunoconj Radiopharm 1992, 5:367-384
116. 3]-octreotide the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993, 20:716-731.
117. Ur E, Mather SJ, Bomanji J, et al. Pituitary imaging using a labelled somatostatin analogue in acromegaly Clin Endocrinol (Oxford) 1992; 36.147-150.
118. Acromegaly Therapy Consensus Development Panel. Consensus Statement benefits versus risks of medical therapy for acromegaly. Am J Med 1994; 97:468-473.
119. Melmed S. Comprehensive management of acromegaly. Metabolism 1995; 44 (suppl 1) 27-30.
120. Frohman L. Therapeutic options in acromegaly. J Clin Endocrinol Metab 1991; 72:1 175-1.181.
121. Melmed S. Medical management of acromegaly-what and when? Acta Endocrinol (Copenh) 1993; 129 (suppl 1):13-17
122. Quabbe HJ Acromegaly: objectives of therapy. En: Lamberts SWJ. ed. Sandostatin in the Treatment of Acromegaly. Berlin: Springer-Verlag. 1988; 17-22.
123. Eastman RC, Gorden P, Roth J. Conventional supervoltage irradiation is an effective Treatment of Acromegaly J Clin Endocrinol Metab 1979; 48:931-940
124. Serri O, Somma M, Comtois R, et al. Acromegaly biochemical assessment of cure after long term follow-up of transsphenoidal selective adenomectomy. J Clin Endocrinol Metab 1985. 61,1.185-1.189.
125. Klibanski A, Zervas NT. Diagnosis and management of hormone secreting pituitary adenomas N Engl J Med 1991; 324:822-831
126. Fahlbusch F, Honegger J, Buchfelder M. Surgical management of acromegaly. Endocrinol Metab Clin North Am 1992; 21:669-692.
127. Eastman RC, Gorden P, Glastein E, Roth J. Radiation therapy of acromegaly. Endocrinol Metab Clin North Am 1992. 21:693-712.
128. Wen PY, Loeffler JS. Advances in the diagnosis and management of pituitary tumors Curr Opin Oncol 1995; 7:56-62.
129. Jenkins D, Stewart PM. Advances in medical therapy for pituitary disease: treating patients with growth hormone excess and deficiency. J Clin Pharm Ther 1993; 18:155-163.
130. Aron DC, Tyrrell JB, Wilson CB. Pituitary tumors Current concepts in diagnosis and management West J Med 1995; 162:340-352.
131. Krishna AY, Phillips LS. Management of acromegaly: a review Am J Med Sci 1994, 308:370-375.
132. a ed). St Louis: Mosby. 1994; 44-48
133. Serra Payro JM, Viñals Viñals JM, Palacín Porte JA, et al Surgical management of the acromegalic face. J Craniofac Surg 1994; 5:336-338.
134. Ross DA, Wilson CB. Results of transspherioidal microsurgery for growth hormone-secreting pituitary adenomas in a series of 214 patients. J Neurosurg 1988; 68:854-867
135. Landolt AM, Illig R, Zapf J. Surgical treatment of acromegaly. En: Lamberts SWJ. ed. Sandostatin in the Treatment of Acromegaly. Berlin: Springer-Verlag, 1988: 23-35.
136. Astrup J, Kjaersgaard JO, Damsgaard EM. Neurokirurgisk behandling af akromegali. Ugeskr Laeger 1993; 155.2 142-2.147
137. Davis DH, Laws ER Jr, Ilstrup DM, et al. Results of surgical treatment for growth hormone-secreting pituitary adenomas. J Neurosurg 1993; 79.70-75.
138. Tindall GT, Oyesiku NM, Watts NB, et al. Transsphenoldal adanomectomy for growth hormone-secreting pituitary adenomas in acromegaly: outcome analysis and determinants of failure, J Neurosurg 1993; 78-205-215.
139. Osman IA, James RA, Chatterjee S, et al. Factors determining the long-term outcome of surgery for acromegaly. Q J Med 1994; 87:617-623.
140. Puchner MJ, Knappe UJ, Ludecke DK. Pituitary surgery in elderly patients with acromegaly. Neurosurgery 1995; 36:677-684.
141. Laws ER, Thapar K. Surgical management of pituitary adenomas. Baillière's Clin Endocrinol Metab 1995; 9:391-405.
142. Vance ML, Harris AG. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Arch Intern Med 1991; 151:1.573-1 578.
143. Quabbe HJ. Treatment of acromegaly by trans-sphenoidal operation, 90-yttrium implantation, and bromocriptine: results in 230 patients. Clin Endocrinol (Oxford) 1982; 16:107-119.
144. Grisoli F, Leclercq T, Jacquet P, et al. Transsphenoidal surgery for acromegaly. Long-term results in 100 patients. Surg Neurol 1985; 23:513-519.
145. Roth J, Gorden P, Brace K. Efficacy of conventional pituitary irradiation in acromegaly. N Engl J Med 1970; 282:1 385-1.391.
146. Lawrence AM, Pinsky SM, Goldfine ID. Conventional radiation therapy in acromegaly. A review and reassessment. Arch Intern Med 1971: 128:369-377
147. Halberg FE, Sheline GE. Radiotherapy of pituitary tumors. Endocrinol Metab Clin North Am 1987; 16:667-684
148. Clarke SD, Woo SY, Butler EB, et al Treatment of secretory pituitary adenoma with radiation therapy. Radiology 1993; 188:759-763.
149. Goffman TE, Dewan R, Arakaki R, et al. Persistent or recurrent acromegaly. long-term endocrinologic efficacy and neurologic safety of post-surgical irradiation. Cancer 1992; 69:271-275.
150. Lamberg BA, Kivikangas V, Vartiainen J, et al. Conventional pituitary irradiation in acromegaly. Effect on growth hormone and TSH secretion. Acta Endocrinol (Copenh) 1976; 82:267-281.
151. Wass JAH, Ciccarelli E, Corsello S, et al External radiation therapy of acromegaly En: Lamberts SWJ, ed. Sandostatin in the Treatment of Acromegaly. Berlin: Spnnger-Verlag, 1988; 37-43.
152. Plowman PN. Radiotherapy for pituitary tumours. Bailliere's Clin Endocrinol Metab 1995; 9:407-420.
153. Feek CM, McLelland J, Seth J, et al. How effective is external pituitary irradiation for growth hormone-secreting pituitary tumors? Clin Endocrinol (Oxford) 1984, 20:401-408.
154. Shih TY, Wei CP, Lui CC, Leung W. Magnetic resonance imaging of radiation necrosis after radiotherapy for acromegaly: report of a case. J Formos Med Assoc 1994, 93:78-80
155. Kjellberg RN, Kliman B, Swisher BJ Radiosurgery for pituitary adenoma with bragg peak proton beam. En: Derome PJ, Jedynak CP, Peillon F, eds. Pituitary adenomas. Paris: Asclepios Publishing. 1980; 209-217.
156. Ostertag CB. Stereotaktische Radiochirurgie. Nervenarzt 1994; 65:660-669
157. Pollock BE, Kondziolka D, Lunsford LD, Flickinger JC. Stereotactic radiosurgery for pituitary adenomas: imaging, visual and endocrine results. Acta Neurochir (Wien) 1994; 62 (suppl):33-38.
158. Vance ML, Evans WS, Thorner MO. Bromocriptine. Ann Intern Med 1984, 100:78-91
159. Wass JA, Thorner MO, Morris DV, et al. Long-term treatment of acromegaly with bromocriptine. Br Med J 1977; 1-875-878.
160. Von Werder K. Bromocriptine treatment of acromegaly. En: Lamberts SWJ. ed, Sandostatin in the Treatment of Acromegaly. Berlin: Springer-Verlag. 1988, 45-52.
161. Rau H, Althoff PH, Schmidt K, et al. Bromocriptine treatment over 12 years in acromegaly: effect on glucose tolerance and insulin secretion. Clin Invest 1993; 71:372-378.
162. Besser GM, Wass JAH, Thorner MO. Bromocriptine in the medical management of acromegaly. Adv Biochem Psychopharmacol 1980; 23:191-198.
163. Carlson HE, Levin SR, Braunstein GD, et al. Effect of bromocriptine on serum hormones in acromegaly. Hormone Res 1984; 19:142-152
164. Jaffe CA, Barkan AL Treatment of acromegaly with dopamine agonists Endocrinol Metab Clin North Am 1992; 21:713-735.
165. Wass JAH, Laws ER Jr, Randall RV, Sheline GE. The treatment of acromegaly. Clin Endocrinol Metab 1986, 15:683-707.
166. Jaspers C, Haase R, Pfingsten H, et al. Long-term treatment of acromegalic patients with repeatable parenteral depot-bromocriptine. Clin Invest 1993, 71.547-551
167. Nordmann R, Widmer A. Resolution and absolute configuration of the potent dopamine agonist N,N-diethyl-N'-[(3a, 4aa, 10ab)-1,2,3,4, 4a,5,10,10a-octahydro-6-hydroxy-1-propyl-3-benzo[g]quinolinyl] sulfamide. J Med Chem 1985; 28:1 540-1.542.
168. Rasmussen C, Bergh T Wide L, Browell J. CV 205-502: a new long-acting drug for inhibition of prolactin hypersecretion. Clin Endocrinol (Oxford) 1987: 26:321-326.
169. Chiodini PG, Attanasio R, Cozzi R, et al CV 205-502 in acromegaly Acta Endocrinol (Copenh) 1993; 128:389-393
170. Lombardi G, Colao A, Ferone D, et al. CV 205-502 treatment in therapy-resistant acromegalic patients Eur J Endocrinol 1995; 132-559-564.
171. Arimura A. Recent progress in somatostatin research. Biomed Res 1981. 2:233-257.
172. Wass JAH. Somatostatin and its physiology in man in health and disease. En: Martin L, Besser GM, eds. Clinical Neuroendocrinology. vol II. Nueva York: Academic Press. 1982, 359-395.
173. Gottesman IS, Mandraino LJ, Gerich JE. Somatostatin: its role in health and disease. Special Topics Endocrinol Metab 1982, 4.177-243.
174. Reichlin S, Somatostatin N Engl J Med 1983; 309:1.495-1 501. 1.556-1 563.
175. Gómez-Pan A, Rodríguez-Arnao MD. Somatostatin and growth hormone releasing factor: synthesis, location, metabolism and function. Clin Endocrinol Metab 1983, 12.469-507.
176. Gómez-Pan A, Sastre J, Díez JJ. Somatostatina. desde el hipotálamo hasta el eje gastroenteropancreático. En Blázquez E, Tamarit J, eds. Péptidos reguladores gastrointestinales y recepción y transducción de señales generadas por hormonas peptídicas, tiroideas y esteroideas. Madrid. Fundación Ramón Areces, 1992: 127-184.
177. Astorga Jiménez R. Análogo de la somatostatina: perspectivas actuales y futuras Med Clin (Barc) 1988; 93:508-515.
178. Lamberts SWJ. The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. Endocrine Rev 1988, 9:417-436.
179. Longnecker SM. Somatostatin and octreotide: literature review and description of therapeutic activity in pancreatic neoplasia Drug Intell Clin Pharm 1988; 22:99-106
180. Rosenberg JM. Octreotide: a synthetic analog of somatostatin. Drug Intell Clin Pharm 1988; 22:748-754
181. Bauer W, Briner U, Doepfner W, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolongued action. Life Sci 1982; 3:1 133-1.140.
182. Pless J, Bauer W, Bhner U, et al. Chemistry and pharmacology of SMS 201-995. a long-acting octapeptide analog of somatostatin. Scand J Gastroenterol 1986: 21 (suppl 119):54-64.
183. Díez JJ, Salvador J, Gómez-Pan A. Aplicaciones actuates y nuevas perspectivas terapéuticas de los análogos de somatostatina. Endocrinologia 1992, 39:456-467.
184. Plewe G, Beyer J, Krause U, et al. Long acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly. Lancet 1984; 2.782-784
185. Ch'ng LJC, Sandler LM, Kraenzlin ME, et al Long-term treatment of acromegaly with a long-acting analogue of somatostatin. Br Med J 1985, 290.284-285.
186. Lamberts SWJ, Oosteron R, Neufeld M, Del Pozo E. The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab 1985; 60:1 161-1.165.
187. Jackson I, Barnard LB, Lamberton P. Role of a long-acting somatostatin analogue (SMS 201-995) in the treatment of acromegaly. Am J Med 1986; 81:94-99.
188. Barnard LB, Grantham WG, Lamberton P, et al. Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201-995). Ann Int Med 1986; 105 856-861.
189. Williams G, Ball JA, Burrin JM, et al. Effective and lasting growth hormone suppression in active acromegaly with oral administration of somatostatin analogue SMS 201-995. Lancet 1986; 2:774-777.
190. Harns AG, Prestele H, Herold K, Boerlin V. Long term efficacy of Sandostatin (SMS 201-995, octreotide) in 178 acromegalic patients. Results from the international multicentre acromegaly study group. En. Lamberts SWJ, ed. Sandostatin in the treatment of acromegaly. Concensus round table. Amsterdam. Berlin: Springer. 1987; 117-125
191. Chiodini PG, Cozzi R, Dallabonzana D, et al. Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine. J Clin Endocrinol Metab 1987; 64.447-453.
192. Comi RJ, Gorden P. The response of serum growth hormone levels to the long acting somatostatin analog SMS 201-995 in acromegaly. J Clin Endocrinol Metab 1987, 64:37-42.
193. Harris AG, Prestele H, Herold K, Boerlin V. Long-term efficacy of sandostatin (SMS 201-995, octreotide) in 178 acromegalic patients. Results from the International Multicentre Acromegaly Study Group. En. Lamberts SWJ. ed Sandostatin in the Treatment of Acromegaly Berlin: Springer-Verlag, 1988; 117-125.
194. Tollis G. Long-term management of acromegaly with sandostatin. Horm Res 1988, 29-112-114.
195. Barkan AL, Kelch RP, Hopwood NJ, Beitins IZ. Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995. J Clin Endocrinol Metab 1988; 66:16-23
196. Lamberts SWJ Studies on the acute and chronic effects of Sandostatin in acromegaly. En: Lamberts SWJ, ed. Sandostatin in the Treatment of Acromegaly Berlin Springer-Verlag, 1988; 62-74.
197. Horikawa R, Takano K, Hizuka N, et al. Treatment of acromegaly with long acting somatostatin analogue SMS 201-995. Endocrinol Japon 1988; 35:741-751.
198. Halpenn I, Vendrell J, Conget I, et al. Tratamiento prolongado de la acromegalia con el análogo de la somatostatina SMS 201-995 Endocrinología 1989, 36:49-53.
199. Quabbe HJ, Plöckinger U. Treatment of acromegaly with the somatostatin analogue SMS 201-995 (Sandostatin). En: Lamberts SWJ, ed Sandostatin in the Treatment of Acromegaly Berlin: Springer-Verlag. 1988, 81-82.
200. Sassolas G, Fossati P, Chanson P, et al. Effects of long-term administration of Sandostatin (SMS 201-995) at increasing doses in 40 acromegalic patients Results from the French Sandostatin Acromegaly Study Group. En: Lamberts SWJ. ed. Sandostatin in the Treatment of Acromegaly. Berlin: Springer-Verlag, 1988: 89-94.
201. Tauber JP, Babin TH, Ducasse MCR, et al. Long-term treatment of acromegaly by continuous subcutaneous infusion of the long-term somatostatin analog Sandostatin (SMS 201-995, octreotide) En: Lamberts SWJ. ed. Sandostatin in the Treatment of Acromegaly. Berlin Springer-Verias, 1988; 109-112.
202. Quabbe HJ, Plöckinger U. Dose-response study and long-term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly J Clin Endocrinol Metab 1989, 68:873-880.
203. Astorga R. SMS 201-995 (Sandostatin) en acromegalia. En: Diëguez C, Casanueva F, Gömez-Pan A, Charro A, eds. Perspectives futuras de los anäloges de la somatostatina. Santiago de Compostela: Universidad de Santiago de Compostela. 1990; 25-44.
204. Sassolas G, Harris AG, James-Deidier A. The French SMS 201-995 acromegaly study group Long-term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. J Clin Endocrinol Metab 1990, 71:391-397.
205. Ho KY, Weissberger AJ, Marbach P, Lazarus L. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and
206. Lamberts SWJ, Reubi JC, Krenning EP. Somatostatin analogs in the treatment of acromegaly. Endocrinol Metab Clin North Am 1992; 21:737-752
207. Arosio M, Macchelli S, Rossi CM, et al The Italian Multicenter Octreotide Study Group. Effects of treatment with octreotide in acromegalic patients-a multicenter Italian study. Eur J Endocrinol 1995; 133:430-439.
208. Plöckinger U, Liehr RM, Quabbe HJ. Octreotide long term treatment of acromegaly: effect of drug withdrawal on serum growth hormone/insulin-like growth factor-I concentrations and on serum gastrin/24-hour intragastric pH values. J Clin Endocrinol Metab 1993; 77:157-162.
209. Harris AG, Kokoris SP. Applications therapeutiques de la somatostatine et de son analogue, l'octreotide Press Med (Paris) 1993; 22:724-733
210. Ezzat S, Horvath E, Harris AG, Kovacs K Morphological effects of octreotide on growth hormone-producing pituitary adenomas. J Clin Endocrinol Metab 1994, 79:113-118.
211. Hansen TB, Gram J, Bjerre P, et al. Body composition in active acromegaly during treatment with octreotide: a double-blind, placebocontrolled cross-over study. Clin Endocrinol (Oxford) 1994, 41.323-329.
212. Candrina R. Octreotide in the management of active acromegaly due to inoperable growth hormone-secreting adenoma. Recenti Prog Med 1994; 85:13-19.
213. McKnight JA, McCance DR, Sheridan B, Atkinson AB. Four years' treatment of resistant acromegaly with octreotide. Eur J Endocrinol 1995, 132.429-432
214. Yang IM, Woo JT, Kim SW, et al. Characteristics of acromegalic patients with a good response to octreotide, a somatostatin analogue. Clin Endocrinol (Oxford) 1995, 42:295-301
215. Barreca A, Cariola G, Ponzani P, et al. Effect of octreotide on circulating IGF-1 Chromatographic profile, evidence for an inhibitory action on the formation of the 150-kDa ternary complex. Clin Endocrinol (Oxford) 1995; 42.161-167.
216. Halse J, Harris AG, Kvistborg A, et al. A randomized study of SMS 201-995 versus bromocriptine treatment in acromegaly. clinical and biochemical effects. J Clin Endocrinol Metab 1990; 70:1.254-1.261.
217. Timsit J, Chanson P, Larger E, et al. The effect of subcutaneous infusion versus subcutaneous injections of a somatostatin analogue (SMS 201-995) on the diurnal GH profile in acromegaly Acta Endocrinol (Copenh) 1987: 116 108-112.
218. Tauber JP, Babin T, Tauber MT, et al. Long term effects of a continuous subcutaneous infusion of the somatostatin analogue octreotide in the treatment of acromegaly J Clin Endocrinol Metab 1989; 68:917-924.
219. Christensen SE, Weeke J, Orskov H, et al. Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients. Clin Endocrinol (Oxford) 1987; 27:297-306
220. Wang C, Lam KSL, Arceo E, Chan FL. Comparison of the effectiveness of 2-hourly versus 8-hourly subcutaneous injections of a somatostatin analog (SMS 201-995) in the treatment of acromegaly J Clin Endocrinol Metab 1989; 69-670-677
221. Page MD, Millward ME, Hourthan M, et al. Long-term treatment of acromegaly with octreotide (Sandostatin). Horm Res 1990; 33:20-31.
222. White MC, James RA, Chatterjee S, et al Administration of highdose octreotide (Sandostatin) by continuous subcutaneous infusion for the treatment of acromegaly Horm Res 1990, 33 13-19.
223. Ezzat S, Snyder P, Young WF, et al. Octreotide treatment of acromegaly: a randomized, multicenter study. Ann Intern Med 1992; 117:711-718
224. Giusti M, Cuttica CM, Cariola G, et al Treatment of acromegaly with octreotide: effectiveness and tolerability of its pulsatile administration by portable pump. Recenti Prog Med 1995; 86:189-194.
225. Harris AG, Kokons SP, Ezzat S. Continuous versus intermitent subcutaneous infusion of octreotide in the treatment of acromegaiy. J Clin Pharmacol 1995 35:59-71
226. Roelfsema F, Frölich M, De Boer H, Harris AG. Octreotide treatment in acromegaly: a comparison between pen-treated and pump-treated patients in a cross-over study. Acta Endocrinol (Copenh) 1991; 125:43-48.
227. James RA, White MC, Chatterjee S, et al. Comparison of octreotide delivered by continuous subcutaneous infusion with intermitent injection in the treatment of acromegaly Eur J Clin Invest 1992; 22:554-561
228. Liuzzi A, Chiodini PG, Cozzi R, et al Medical treatment of acromegaly. Dopaminergic agonists and long-acting somatostatin. En: Lamberts SWJ, ed. Sandostatin in the Treatment of Acromegaly. Berlin: Springer-Verlag, 1988; 76-79.
229. Wagenaar AH, Harris AG, Van der Lely, Lamberts SWJ. Dynamics of the acute effects of octreotide, bromocriptine and both drugs in combination on growth hormone secretion in acromegaly Acta Endocrinol (Copenh) 1991; 125.637-642.
230. Fredstorp L, Kutz K, Werner S. Treatment with octreotide and bromocriptine in patients with acromegaly: an open pharmacodynamic interaction study. Clin Endocrinol (Oxford) 1994; 41:103-108.
231. Flogstad AK, Halse J, Grass P, et al. A comparison of octreotide, bromocriptine. or a combination of both drugs in acromegaly J Clin Endocrinol Metab 1994; 79:461-465.
232. Lamberts SW, Zweens M, Klijn JG, et al The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly. Clin Endocrinol (Oxford) 1986; 25:201-212.
233. Weeke J, Christensen SE, Ørskov H, et al. A randomised comparison of infranasal and injectable octreotide administration in patients with acromegaly. J Clin Endocrinol Metab 1992; 75:163-169.
234. Lancranjan I, Bruns C, Grass P, et al Sandostatin LAR®: pharmacokinetics, pharmacodynamics, efficacy, and tolerability in acromegalic patients. Metabolism 1995; 44 (suppl 1): 18-26.
235. Priou A, Levesque G, Simonetta C, et al. La sandostatine retard (sandostatine LAR) dans le traitement de l'acromegalie. Ann Endocrinol (Paris) 1995; 56:213-218
236. Kaal A, Frystyk J, Skjaerbaek C, et al Effects of intramuscular microsphere-encapsulated octreotide on serum growth hormone, insulin-like growth factors (IGFs). free IGFs, and IGF-binding proteins in acromegalic patients. Metabolism 1995; 44 (suppl 1)-6-14.
237. Sassolas G, Khalfallah Y, Chayvialle JA, et al. Effects of the somatostatin analog BIM 23014 on the secretion of growth hormone, thyrotropin, and digestive peptides in normal men. J Clin Endocrinol Metab 1989; 68 239-246
238. Kuhn JM, Basin C, Beaudoin C, et al. Influence de la dose et des modalités d'administration du BIM 23014 sur la sécrétion d'hormone de croissance de l'acromegalie. Ann Endocrinol (Paris) 1992, 53:208-214.
239. Kuhn JM, Basin C, Mollard M, et al. Effects of the new somatostatin analogue (BIM 23014) on blood glucose homeostasis in normal men. Eur J Clin Invest 1992, 22:793-799.
240. Kuhn JM, Basin C, Mollard M, et al. Pharmacokinetic study and effects on growth hormone secretion in healthy volunteers of the new somatostatin analogue BIM 23014. Eur J Clin Pharmacol 1993; 45: 73-77.
241. Kuhn JM, Legrand A, Ruiz JM, et al. Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers. Br J Clin Pharmacol 1994; 38:213-219
242. Boucekkine C, Catus F, Blumberg-Tick J, et al Traitement de l'acromegalie par un nouvel analogue de la somatostatine, le lanréotide à action prolongée. Ann Endocrinol (Paris) 1994; 55:261-269.
243. Wolthers T, Grafte T, Flyvbjerg A, et al Dose-dependent stimulation of insulin-like growth factor-binding protein-1 by lanreotide, a somatostatin analog. J Clin Endocrinol Metab 1994, 78.141-144.
244. Heron I, Thomas F, Dero M, et al. Traitement de l'acromegalie par une forme à libération prolongée du lanréotide Un nouvel analogue de la somatostatine. Presse Méd (Paris) 1993; 22:526-531.
245. Heron I, Thomas F, Dero M, et al. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly J Clin Endocrinol Metab 1993, 76:721-727.
246. Morange I, De Boisvilliers F, Chanson P, et al Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide J Clin Endocrinol Metab 1994; 79.145-151.
247. Marek J, Hána V, Krsek M, et al. Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide. Eur J Endocrinol 1994. 131:20-26.
248. Johnson MR, Chowdrey HS, Thomas F, et al. Pharmacokinetics and efficacy of the long-acting somatostatin analogue somatuline in acromegaly. Eur J Endocrinol 1994, 130.229-234
249. Caron P, Cogne M, Gusthiot-Joudet B, et al. Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995). Eur J Endocrinol 1995, 132-320-325
250. Schmidt K, Althoff PH, Harris AG. Analgesic effect of the somatostatin analogue octreotide in two acromegalic patients: a double-blind study with long-term follow-up. Pain 1993, 53:223-227.
251. Chanson P, Timsit J, Masquet C, et al Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Ann Intern Med 1990: 113:921-925
252. Merola B, Cittadini A, Colao A, et al. Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly. J Clin Endocrinol Metab 1993: 77:790-793.
253. Giustina A, Boni E, Romanelli G, et al. Cardiopulmonary performance during exercise in acromagly, and the effects of acute suppression of growth hormone hypersecretion with octreotide. Am J Cardiol 1995: 75:1.042-1.047.
254. Barkan AL, Lloyd RV, Chandler WF, et al. Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 1988; 67:1.040-1.048.
255. Barakat S, Melrned S. Reversible shrinkage of a growth hormone-secreting pituitary adenoma by a long-acting somatostatin analogue, octreotide. Arch Intern Med 1989, 149:1.443-1 445.
256. Ducasse MCR, Tauber JP. Tourre A, et al. Shrinking of a growth hormone-producing pituitary tumor by continuous subcutaneous infusion of the somatostatin analog SMS 201-995. J Clin Endocrinol Metab 1987; 65:1.042-1.046.
257. Lucas-Morante T, García-Uría J, Estrada J, et al. Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery. J Neurosurg 1994. 81:10-14.
258. Lamberts SWJ, Uitterlinden P, Vershoor L, et al. Long-term treatment of acromegaly with the somatostatin analog SMS 201-995. N Engl J Med 1985: 313:1.576-1.580.
259. Spinas GA, Zapf J, Landolt AM, et al. Pre-operative treatment of 5 acromegalics with a somatostatin analogue: endocrine and clinical observation Acta Endocrinol (Copenh) 1987; 114:249-256.
260. Tolis G, Yotis A, Del Pozo E, Pitaulis S. Therapeutic efficacy of a somatostatin analogue (SMS 201-995) in active acromegaly. J Neurosurg 1986: 65:37-40.
261. Van Liessum PA, Hopman WPM, Pieters GFFM, et al. Postprandial gallbladder motility during long-term treatment with the long-acting somatostatin analog SMS 201-995 in acromegaly. J Clin Endocrinol Metab 1989, 69:557-562.
262. Catnach SM, Anderson JV, Fairclough PD, et al. Effect of octreotide on gall stone prevalence and gall bladder motility in acromegaly. Gut 1993; 34:270-273.
263. Dowling RH, Hussaini SH, Murphy GM, Wass JA. Gallstones during octreotide therapy. Digestion 1993; 54 (suppl 1):107-120.
264. Eastman RC, Arakiki RF, Shawker T, et al. A prospective examination of octreotide-inducad gallbladder changes in acromegaly. Clin Endocrinol (Oxford) 1992; 36.265-269.
265. Wass JAH, Anderson JV, Besser GM, Dowling RH. Gallstone and treatment with octreotide for acromegaly. Br Med J 1989; 299:1.162-1.163.
266. Wass JA. Octreotide treatment ot acromegaly. Horm Res 1990; 33.1-12.
267. Bigg-Wither GW, Ho KKY, Grunstein RR, et al. Effects of long term octreotide on gallstone formation and gallbladder function. Br Med J 1992; 304:1.611-1612.
268. Shi YF, Zhu XF, Harris AG, et al. Prospective study of the longterm effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients. J Clin Endocrinol Metab 1993; 76:32-37.
269. Erlinger S, Chanson P, Dumont M, et al. Effects of octreotide on biliary lipid composition and occurrence of cholesterol crystals in patients with acromegaly Dig Dis Sci 1994; 39:2.384-2 388.
270. McKnight JA, McCance DR, Crothers JG, Atkinson AB Changes in glucose tolerance and development of gallstones during high dose treatment with octreotide for acromegaly Br Med J 1989; 299:1 604-1.605.
271. Jackson JA. Complications of long-acting somatostatin analogue therapy. Am J Med 1989; 86 512-513.
272. Shi YF, Hams AG, Zhu XF, Deng JY Clinical and biochemical effects of incremental doses of the long-acting analogue SMS 201-995 in ten acromegalic patients. Clin Endocrinol (Oxford) 1990; 33.695-705.
273. Montini M, Gianola D, Pagani MD, et al. Cholelithiasis and acromegaly therapeutic strategies. Clin Endocrinol (Oxford) 1994; 40-401-406.
274. Redfern JS, Fortuner WJ 2nd. Octreotide-associated biliary tract dysfunction and gallstone formation pathophysiology and management. Am J Gastroenterol 1995; 90-1 042-1 052.
275. Hussaini SH, Pereira SP, Murphy GM, et al. Composition of gall bladder stones associated with octreotide: response to oral ursodeoxycholic acid. Gut 1995, 36:126-132
276. Koop BL, Harris AG, Ezzat S. Effect of octreotide on glucose tolerance on acromegaly. Eur J Endocrinol 1994; 130:581-586
277. Levitt NS, Ratanjee BD, Abrahamson MJ. Do «so-called» normal growth hormone concentrations (2-5 micrograms/1) indicate cure in acromegaly? Horm Metab Res 1995; 27:185-188.
278. Fahlbusch R, Giovanelli M, Buchfelder M, Losa M. Advances in the medical and surgical treatment of pituitary adenomas: the role of long-acting somatostatin analogs. J Endocrinol Invest 1993; 16:449-460
279. Stevenaert A, Beckers A. Presurgical octreotide treatment in acromegaly. Acta Endocrinol (Copenh) 1993; 129 (suppl 1):18-20.